Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Vaccine R&D - the pace is too slow
- Vaccine R&D - failure rate too high
- New paradigm required
- Vaccine R&D - too slow, failure rate too high
- Bridge barriers between research & translation
- Translating scientific innovation to HIV vaccine?
- Inducing broadly neutralizing antibodies (bNAbs)
- What does nature do?
- What nature did - the CD4bs BNAb CH103
- Affinity-based immunogen design
- What is required for mimicking nature
- Rules for primary & secondary response (1)
- Rules for primary & secondary response (2)
- Rules for secondary-tertiary response
Topics Covered
- Vaccine R&D: too slow, high failure rate
- HIV vaccine goal: induce broadly neutralizing antibodies (bNAb)
- Mimicking nature to create bNAb
- Rules for inducing primary response with memory B cell breadth
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Wilson, C. (2015, May 28). Future directions for vaccine discovery 1 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 13, 2024, from https://doi.org/10.69645/NZOT4594.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Chris Wilson has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Future directions for vaccine discovery 1
Published on May 28, 2015
30 min
Other Talks in the Series: Vaccines
Transcript
Please wait while the transcript is being prepared...
0:00
This is Chris Wilson.
I'm the Director of Discovery
& Translational Sciences
at the Bill and Melinda
Gates Foundation
in Seattle, Washington,
United States.
And what I'd like to
speak with you today about
is some future directions
for vaccine discovery
and how innovation
in vaccine discovery
can have a positive impact
on global health inequities.
As most of you may
know, vaccines are
one of the most impactful and
cost-effective public health
measures of the 20th century.
However, there remain
great unmet needs
to develop vaccines for globally
burdensome infectious diseases
and to allow more timely
responses to emerging
infectious disease threats.
0:38
As shown in the cartoon
along the top of this slide,
the path by which new vaccines
are discovered and developed
is challenging and
often long and costly.
In fact, the shortest time taken
from identification of the microbe,
which would be at the far left of
the chevron shown along the top,
to the launch of a vaccine
has been nine years.
And that was the measles vaccine,
which stood on the shoulders, that
is to say, built off of a
precedent established by the Sabin
polio vaccine, thus
making it an easier
process than for most vaccines.
As you can also see, there is at
least one major infectious disease
for which we've identified the
pathogen more than 115 years ago
and still do not have a
vaccine and that is malaria.
Thus historically, the
range of time required
to go from identification of a
pathogen to an effective vaccine
is fundamentally too long.
Even once one has advanced
a potential product
through exploratory and is ready
to take it into development,
8 to 10 years is currently
required for a typical vaccine.